Skip to content
The Nexus
DossierENTITY

Immunic

Coverage of Immunic in the Nexus archive.

Earliest in view: May 8 · 14:41 UTCMost recent: Aug 11 · 10:35 UTC
Co-mentioned in this coverage
IMUXtopic1New Yorkplace1APorganization1Zacks Investment Researchorganization1Automated Insightsorganization1Michael Panzaraperson1Neurvati Neurosciencesorganization1
Recent coverage
  • BUSINESSAug 11 · 10:35 UTCWTOP DC
    Immunic: Q2 Earnings Snapshot

    Immunic, Inc. reported a loss of $34.1 million in its second quarter, reporting 80 cents per share loss. These results surpassed Wall Street expectations. The average estimate from six analysts surveyed by Zacks Investment Research was for a loss of $1.24 per share.

  • HEALTHMay 8 · 14:41 UTCSTAT NEWS
    STAT+: Up and down the ladder: The latest comings and goings

    Immunic hired Michael Panzara as chief medical officer, previously holding the same position at Neurvati Neurosciences. This move highlights a key change in the company's leadership. Immunic is expanding its team with new hires and promotions.